Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 5/20 | 0.60 |
| ▸ | RAB9A | P51151 | 5/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | NOTUM | Q6P988 | 3/20 | 0.52 |
| ▸ | TSHR | P16473 | 2/20 | 0.51 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 4/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | DRD2 | P14416 | 1/20 | 0.48 |
| ▸ | DRD4 | P21917 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.47 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.47 |
| ▸ | BCHE | P06276 | 1/20 | 0.47 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.47 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3721043 | 0.92 | NOTUM (0.55) | NPC1RAB9AL3MBTL1ALDH1A1NOTUM | |
| Hydrochloric Acid SCHEMBL7423344 | 0.88 | NPC1 (0.59) | NPC1RAB9AL3MBTL1ALDH1A1NOTUM | |
| SCHEMBL2116912 | 0.82 | NPC1 (0.71) | NPC1RAB9AL3MBTL1ALDH1A1NOTUM | |
| SCHEMBL29554766 | 0.82 | NPC1 (0.71) | NPC1RAB9AL3MBTL1ALDH1A1NOTUM | |
| SCHEMBL5797625 | 0.81 | RAB9A (0.63) | NPC1RAB9AL3MBTL1ALDH1A1NOTUM | |
| SCHEMBL299090 | 0.81 | NPC1 (0.66) | NPC1RAB9AL3MBTL1ALDH1A1NOTUM | |
| SCHEMBL9526349 | 0.81 | NPC1 (0.66) | NPC1RAB9AL3MBTL1ALDH1A1NOTUM | |
| SCHEMBL3721168 | 0.79 | PRMT5 (0.56) | ALDH1A1NOTUMTSHRHRH3POLB | |
| SCHEMBL27882103 | 0.79 | NPC1 (0.71) | NPC1RAB9AL3MBTL1ALDH1A1NOTUM | |
| SCHEMBL30681385 | 0.78 | RAB9A (0.66) | NPC1RAB9AL3MBTL1ALDH1A1NOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102026993-A | New compounds III | BIOVITRUM AB PUBL | 2011-04-20 | — | — | CN | claimed |
| EP-2227461-A1 | NEW COMPOUNDS III | AstraZeneca AB (Publ) (SE) | 2010-09-15 | — | — | EP | claimed |
| US-20090176798-A1 | New compounds III | BIOVITRUM AB (SE) | 2009-07-09 | — | — | US | claimed |
| WO-2009071677-A1 | NEW COMPOUNDS III | BIOVITRUM AB (PUBL) (SE) | 2009-06-11 | — | — | WO | claimed |
| CN-102026993-A | New compounds III | BIOVITRUM AB PUBL | 2011-04-20 | — | — | CN | disclosed |
| EP-2227461-A1 | NEW COMPOUNDS III | AstraZeneca AB (Publ) (SE) | 2010-09-15 | — | — | EP | disclosed |
| US-20090176798-A1 | New compounds III | BIOVITRUM AB (SE) | 2009-07-09 | — | — | US | disclosed |
| US-20090176798-A1 | New compounds III | BIOVITRUM AB (SE) | 2009-07-09 | — | — | US | disclosed |
| US-20090176798-A1 | New compounds III | BIOVITRUM AB (SE) | 2009-07-09 | — | — | US | disclosed |
| WO-2009071677-A1 | NEW COMPOUNDS III | BIOVITRUM AB (PUBL) (SE) | 2009-06-11 | — | — | WO | disclosed |
| WO-2009071677-A1 | NEW COMPOUNDS III | BIOVITRUM AB (PUBL) (SE) | 2009-06-11 | — | — | WO | disclosed |
| EP-2066661-A2 | PHOSPHODIESTERASE INHIBITORS | Ranbaxy Laboratories Limited (IN) | 2009-06-10 | — | — | EP | disclosed |
| WO-2008035316-A2 | PHOSPHODIESTERASE INHIBITORS | RANBAXY LABORATORIES LIMITED (IN) | 2008-03-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090176798-A1 | New compounds III | GPR119, FABP4, GLP1R | NPC1 702/4885RAB9A 4294/4885L3MBTL1 4694/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.